NCT02994082

Brief Summary

This is a pilot study designed in an effort to develop and improve access to effective treatments for tobacco use in rural Veterans using a tailored intervention approach. Specifically, we will evaluate a combined behavioral and pharmacological smokeless tobacco cessation which concomitantly addresses comorbid issues commonly experienced by rural tobacco users including elevated depressive symptoms, risky alcohol use, and concerns about weight gain. The objectives are to:

  1. 1.Evaluate the feasibility of an individually-tailored telephone intervention for rural smokeless tobacco users
  2. 2.Examine the impact of the intervention on treatment utilization, patient satisfaction, and smokeless tobacco cessation.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
123

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Dec 2016

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2016

Completed
7 days until next milestone

First Submitted

Initial submission to the registry

December 8, 2016

Completed
7 days until next milestone

First Posted

Study publicly available on registry

December 15, 2016

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2019

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2020

Completed
Last Updated

July 24, 2019

Status Verified

July 1, 2019

Enrollment Period

2.8 years

First QC Date

December 8, 2016

Last Update Submit

July 22, 2019

Conditions

Keywords

Rural healthVeteransSmokeless tobacco cessation

Outcome Measures

Primary Outcomes (1)

  • Treatment satisfaction

    Participants' impressions of and satisfaction with their assigned intervention will be assessed via interview.

    Three month follow-up

Secondary Outcomes (7)

  • Tobacco use

    Three-and six-month follow-up

  • Alcohol use

    Three- and six-month follow-up

  • Depressive symptoms

    Three- and six-month follow-up

  • Body weight

    Three- and six-month follow-up

  • Enrollment rate

    Six months after study initiation

  • +2 more secondary outcomes

Study Arms (2)

Tailored Intervention

EXPERIMENTAL

The tailored behavioral intervention includes both behavioral and pharmacological components. The behavioral component will consist of six sessions of cognitive behavioral therapy and coping skills training delivered over the telephone. In addition, participants will be screened for conditions commonly associated with tobacco use (depressive symptoms, risky alcohol use, weight concerns) and offered supplementary behavioral treatment modules to address these issues. Participants will also be offered pharmacotherapy for tobacco cessation, with decisions regarding specific medication(s) based on patients' medical history, contraindications, prior experiences, and preferences.

Behavioral: Tailored behavioral interventionBehavioral: Behavioral activation for elevated depressive symptomsBehavioral: Post-cessation weight gain managementBehavioral: Alcohol use risk reductionDrug: Nicotine replacement therapy - transdermal nicotine patchDrug: Nicotine replacement therapy - nicotine lozengeDrug: Nicotine replacement therapy - nicotine gumDrug: Bupropion sustained releaseDrug: VareniclineDrug: Combination nicotine replacement therapyDrug: Combination nicotine replacement therapy + bupropion

Facilitated tobacco quit line referral

ACTIVE COMPARATOR

Participants assigned to this condition will receive information about the VA telephone tobacco quit line and educational materials and encouraged to enroll in treatment. In addition, they will be given information regarding available medications for smoking cessation and encouraged to contact their primary care provider to discuss their options.

Behavioral: Tobacco quit lineBehavioral: Educational materials

Interventions

Participants will receive a standard six session cognitive behavioral intervention for smokeless tobacco cessation combined with supplemental treatment modules based on individual need and preferences.

Tailored Intervention

Participants with elevated depressive symptoms may receive this six session telephone-based behavioral activation intervention.

Tailored Intervention

Participants with concerns about gaining weight after quitting smokeless tobacco use may receive this six session telephone-based behavioral self-management intervention designed to help attenuate post-cessation weight gain.

Tailored Intervention

Participants engaging in risky alcohol use may receive this six session telephone-based behavioral intervention for reducing alcohol use.

Tailored Intervention

Medication selection will be based on individual participant preferences, medical history, and contraindications.

Also known as: Nicotine patch
Tailored Intervention

Medication selection will be based on individual participant preferences, medical history, and contraindications.

Also known as: Nicotine lozenge
Tailored Intervention

Medication selection will be based on individual participant preferences, medical history, and contraindications.

Also known as: Nicotine gum
Tailored Intervention

Medication selection will be based on individual participant preferences, medical history, and contraindications.

Also known as: Zyban
Tailored Intervention

Medication selection will be based on individual participant preferences, medical history, and contraindications.

Also known as: Chantix
Tailored Intervention

Medication selection will be based on individual participant preferences, medical history, and contraindications. Possible combinations include nicotine patch + nicotine lozenge and nicotine patch + nicotine gum.

Tailored Intervention

Medication selection will be based on individual participant preferences, medical history, and contraindications. Possible combinations include nicotine patch + bupropion, nicotine gum + bupropion, and nicotine lozenge + bupropion.

Also known as: Medication selection will be based on individual participant preferences, medical history, and contraindications.
Tailored Intervention

Referral to the Department of Veterans Affairs tobacco telephone quit line.

Facilitated tobacco quit line referral

Information regarding the VA tobacco quit line and associated treatment services, self-help materials for tobacco cessation, and information about tobacco cessation medications available in the VA,

Facilitated tobacco quit line referral

Eligibility Criteria

Age18 Years - 99 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Use smokeless tobacco on a daily basis
  • Be willing to make a quit attempt in the next 30 days
  • Reside in a rural location
  • Receiving care through the Iowa City VA Health Care System or an affiliated community-based outpatient clinic
  • Able to provide informed consent
  • Telephone access
  • Stable residence

You may not qualify if:

  • Planning to move in the next 12 months
  • Terminal illness
  • Unstable psychiatric disorder
  • Incarcerated
  • Institutionalized

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Iowa City VA Healthcare System

Iowa City, Iowa, 52246, United States

Location

MeSH Terms

Conditions

Tobacco UseTobacco Use DisorderTobacco Use Cessation

Interventions

EthanolTobacco Use Cessation DevicesNicotine Chewing GumBupropionVareniclineHealth Records, PersonalContraindications

Condition Hierarchy (Ancestors)

BehaviorSubstance-Related DisordersChemically-Induced DisordersMental DisordersHealth Behavior

Intervention Hierarchy (Ancestors)

AlcoholsOrganic ChemicalsTherapeuticsChewing GumPlant GumsBiopolymersPolymersMacromolecular SubstancesPolysaccharidesCarbohydratesCandyFoodDiet, Food, and NutritionPhysiological PhenomenaFood and BeveragesPropiophenonesKetonesBenzazepinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsQuinoxalinesMedical RecordsRecordsData CollectionEpidemiologic MethodsInvestigative Techniques

Study Officials

  • Mark W. Vander Weg, PhD

    Iowa City VA Health Care System

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
FED
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Reserach Specialist

Study Record Dates

First Submitted

December 8, 2016

First Posted

December 15, 2016

Study Start

December 1, 2016

Primary Completion

September 1, 2019

Study Completion

May 1, 2020

Last Updated

July 24, 2019

Record last verified: 2019-07

Data Sharing

IPD Sharing
Will not share

Locations